BAFF: A local and systemic target in autoimmune diseases

Clinical and Experimental Immunology

Volumn 158, Issue 2, 2009, Pages 155-163

  Moisini, I ^a   Davidson, A ^a  

^a FEINSTEIN INSTITUTE FOR MEDICAL RESEARCH   (United States)

Author keywords

BAFF; Multiple sclerosis; Rheumatoid arthritis; Sj gren's syndrome; SLE

Indexed keywords

ALPHA INTERFERON; APRIL PROTEIN; ATACICEPT; B CELL ACTIVATING FACTOR; B CELL ACTIVATING FACTOR RECEPTOR; B CELL MATURATION ANTIGEN; BELIMUMAB; BETA INTERFERON; CYCLOPHOSPHAMIDE; IMMUNOGLOBULIN G; INTERLEUKIN 6; MYCOPHENOLIC ACID; RITUXIMAB; TRANSMEMBRANE ACTIVATOR AND CAML INTERACTOR;

AUTOIMMUNE DISEASE; AUTOIMMUNITY; B LYMPHOCYTE; CELL COUNT; CELL INTERACTION; CELL MATURATION; CELL SURVIVAL; CLINICAL TRIAL; DENDRITIC CELL; DRUG MEGADOSE; DRUG TARGETING; FOLLICULAR DENDRITIC CELL; GERMINAL CENTER; HUMAN; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOGLOBULIN BLOOD LEVEL; IMMUNOGLOBULIN DEFICIENCY; INFLAMMATORY CELL; INNATE IMMUNITY; LYMPHOCYTE ACTIVATION; LYMPHOID CELL; MEMORY CELL; MULTIPLE SCLEROSIS; NEUTROPHIL; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN INDUCTION; PROTEIN PROTEIN INTERACTION; REVIEW; RHEUMATOID ARTHRITIS; SEQUENCE HOMOLOGY; SJOEGREN SYNDROME; STROMA CELL; SYSTEMIC LUPUS ERYTHEMATOSUS; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION;

ANIMALS; AUTOIMMUNE DISEASES; AUTOIMMUNITY; B-CELL ACTIVATING FACTOR; B-CELL ACTIVATION FACTOR RECEPTOR; HUMANS; MICE; TUMOR NECROSIS FACTOR LIGAND SUPERFAMILY MEMBER 13;

EID: 70349658717     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/j.1365-2249.2009.04007.x     Document Type: Review

References (94)

1. Phan TG, Green JA, Gray EE, Xu Y, Cyster JG. Immune complex relay by subcapsular sinus macrophages and noncognate B cells drives antibody affinity maturation. Nat Immunol 2009 10 : 786 793.
2. Mamula MJ. Epitope spreading: the role of self peptides and autoantigen processing by B lymphocytes. Immunol Rev 1998 164 : 231 239.
3. Roosnek E, Lanzavecchia A. Efficient and selective presentation of antigen-antibody complexes by rheumatoid factor B cells. J Exp Med 1991 173 : 487 489.
4. Lund FE. Cytokine-producing B lymphocytes - key regulators of immunity. Curr Opin Immunol 2008 20 : 332 338.
5. Ngo VN, Cornall RJ, Cyster JG. Splenic T zone development is B cell dependent. J Exp Med 2001 194 : 1649 1660.
6. Lipsky PE. Systemic lupus erythematosus: an autoimmune disease of B cell hyperactivity. Nat Immunol 2001 2 : 764 766.
7. Cassese G, Lindenau S, de Boer B et al. Inflamed kidneys of NZB/W mice are a major site for the homeostasis of plasma cells. Eur J Immunol 2001 31 : 2726 2732.
8. Takemura S, Braun A, Crowson C et al. Lymphoid neogenesis in rheumatoid synovitis. J Immunol 2001 167 : 1072 1080.
9. Cancro MP. The BLyS/BAFF family of ligands and receptors: key targets in the therapy and understanding of autoimmunity. Ann Rheum Dis 2006 65 (Suppl. 3 iii34 6.
10. Thien M, Phan TG, Gardam S et al. Excess BAFF rescues self-reactive B cells from peripheral deletion and allows them to enter forbidden follicular and marginal zone niches. Immunity 2004 20 : 785 798.
11. Lesley R, Xu Y, Kalled SL et al. Reduced competitiveness of autoantigen-engaged B cells due to increased dependence on BAFF. Immunity 2004 20 : 441 453.
12. Baccala R, Hoebe K, Kono DH, Beutler B, Theofilopoulos AN. TLR-dependent and TLR-independent pathways of type I interferon induction in systemic autoimmunity. Nat Med 2007 13 : 543 551.
13. Krumbholz M, Theil D, Derfuss T et al. BAFF is produced by astrocytes and up-regulated in multiple sclerosis lesions and primary central nervous system lymphoma. J Exp Med 2005 201 : 195 200.
14. Magliozzi R, Columba-Cabezas S, Serafini B, Aloisi F. Intracerebral expression of CXCL13 and BAFF is accompanied by formation of lymphoid follicle-like structures in the meninges of mice with relapsing experimental autoimmune encephalomyelitis. J Neuroimmunol 2004 148 : 11 23.
15. Nakajima K, Itoh K, Nagatani K et al. Expression of BAFF and BAFF-R in the synovial tissue of patients with rheumatoid arthritis. Scand J Rheumatol 2007 36 : 365 372.
16. Groom J, Kalled SL, Cutler AH et al. Association of BAFF/BLyS overexpression and altered B cell differentiation with Sjogren's syndrome. J Clin Invest 2002 109 : 59 68.
17. Pers JO, Daridon C, Devauchelle V et al. BAFF overexpression is associated with autoantibody production in autoimmune diseases. Ann NY Acad Sci 2005 1050 : 34 9.
18. Seyler TM, Park YW, Takemura S et al. BLyS and APRIL in rheumatoid arthritis. J Clin Invest 2005 115 : 3083 3092.
19. Schiffer L, Bethunaickan R, Ramanujam M et al. Activated renal macrophages are markers of disease onset and disease remission in lupus nephritis. J Immunol 2008 180 : 1938 1947.
20. Mackay F, Silveira PA, Brink R. B cells and the BAFF/APRIL axis: fast-forward on autoimmunity and signaling. Curr Opin Immunol 2007 19 : 327 336.
21. Bossen C, Schneider P. BAFF, APRIL and their receptors: structure, function and signaling. Semin Immunol 2006 18 : 263 275.
22. Gross JA, Johnston J, Mudri S et al. TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease. Nature 2000 404 : 995 999.
23. Bossen C, Cachero TG, Tardivel A et al. TACI, unlike BAFF-R, is solely activated by oligomeric BAFF and APRIL to support survival of activated B cells and plasmablasts. Blood 2008 111 : 1004 1012.
24. Dillon SR, Gross JA, Ansell SM, Novak AJ. An APRIL to remember: novel TNF ligands as therapeutic targets. Nat Rev 2006 5 : 235 246.
25. Ingold K, Zumsteg A, Tardivel A et al. Identification of proteoglycans as the APRIL-specific binding partners. J Exp Med 2005 201 : 1375 1383.
26. Bischof D, Elsawa SF, Mantchev G et al. Selective activation of TACI by syndecan-2. Blood 2006 107 : 3235 3242.
27. Schneider P. The role of APRIL and BAFF in lymphocyte activation. Curr Opin Immunol 2005 17 : 282 289.
28. Tangye SG, Bryant VL, Cuss AK, Good KL. BAFF, APRIL and human B cell disorders. Semin Immunol 2006 18 : 305 317.
29. Woodland RT, Fox CJ, Schmidt MR et al. Multiple signaling pathways promote B lymphocyte stimulator (BLyS)-dependent B cell growth and survival. Blood 2007 111 : 750 760.
30. Enzler T, Bonizzi G, Silverman GJ et al. Alternative and classical NF-kappa B signaling retain autoreactive B cells in the splenic marginal zone and result in lupus-like disease. Immunity 2006 25 : 403 415.
31. Mackay F, Schneider P, Rennert P, Browning J. BAFF and APRIL: a tutorial on B cell survival. Annu Rev Immunol 2003 21 : 231 264. (Pubitemid 37174532)
32. Seshasayee D, Valdez P, Yan M, Dixit VM, Tumas D, Grewal IS. Loss of TACI causes fatal lymphoproliferation and autoimmunity, establishing TACI as an inhibitory BLyS receptor. Immunity 2003 18 : 279 288.
33. Schiemann B, Gommerman JL, Vora K et al. An essential role for BAFF in the normal development of B cells through a BCMA-independent pathway. Science 2001 293 : 2111 2114.
34. Stadanlick JE, Kaileh M, Karnell FG et al. Tonic B cell antigen receptor signals supply an NF-kappaB substrate for prosurvival BLyS signaling. Nat Immunol 2008 9 : 1379 1387.
35. Cancro MP. Peripheral B-cell maturation: the intersection of selection and homeostasis. Immunol Rev 2004 197 : 89 101.
36. Avery DT, Kalled SL, Ellyard JI et al. BAFF selectively enhances the survival of plasmablasts generated from human memory B cells. J Clin Invest 2003 112 : 286 297.
37. Mohr E, Serre K, Manz RA et al. Dendritic cells and monocyte/macrophages that create the IL-6/APRIL-rich lymph node microenvironments where plasmablasts mature. J Immunol 2009 182 : 2113 2123.
38. Shulga-Morskaya S, Dobles M, Walsh ME et al. Factor belonging to the TNF family acts through separate receptors to support B cell survival and T cell-independent antibody formation. J Immunol 2004 173 : 2331 2341.
39. von Bulow GU, van Deursen JM, Bram RJ. Regulation of the T-independent humoral response by TACI. Immunity 2001 14 : 573 582.
40. Rahman ZS, Rao SP, Kalled SL, Manser T. Normal induction but attenuated progression of germinal center responses in BAFF and BAFF-R signaling-deficient mice. J Exp Med 2003 198 : 1157 1169.
41. Kalled SL. Impact of the BAFF/BR3 axis on B cell survival, germinal center maintenance and antibody production. Semin Immunol 2006 18 : 290 296.
42. Sakurai D, Hase H, Kanno Y, Kojima H, Okumura K, Kobata T. TACI regulates IgA production by APRIL in collaboration with HSPG. Blood 2007 109 : 2961 2967.
43. Huard B, McKee T, Bosshard C et al. APRIL secreted by neutrophils binds to heparan sulfate proteoglycans to create plasma cell niches in human mucosa. J Clin Invest 2008 118 : 2887 2895.
44. Castigli E, Scott S, Dedeoglu F et al. Impaired IgA class switching in APRIL-deficient mice. Proc Natl Acad Sci USA 2004 101 : 3903 3908.
45. Mackay F, Schneider P. TACI, an enigmatic BAFF/APRIL receptor, with new unappreciated biochemical and biological properties. Cytokine Growth Factor Rev 2008 19 : 263 276.
46. Boule MW, Broughton C, Mackay F, Akira S, Marshak-Rothstein A, Rifkin IR. Toll-like receptor 9-dependent and -independent dendritic cell activation by chromatin-immunoglobulin G complexes. J Exp Med 2004 199 : 1631 1640.
47. Treml LS, Carlesso G, Hoek KL et al. TLR stimulation modifies BLyS receptor expression in follicular and marginal zone B cells. J Immunol 2007 178 : 7531 7539.
48. Katsenelson N, Kanswal S, Puig M, Mostowski H, Verthelyi D, Akkoyunlu M. Synthetic CpG oligodeoxynucleotides augment BAFF- and APRIL-mediated immunoglobulin secretion. Eur J Immunol 2007 37 : 1785 1795.
49. Groom JR, Fletcher CA, Walters SN et al. BAFF and MyD88 signals promote a lupuslike disease independent of T cells. J Exp Med 2007 204 : 1959 1971.
50. Acosta-Rodriguez EV, Craxton A, Hendricks DW et al. BAFF and LPS cooperate to induce B cells to become susceptible to CD95/Fas-mediated cell death. Eur J Immunol 2007 37 : 990 1000.
51. Ng LG, Sutherland AP, Newton R et al. B cell-activating factor belonging to the TNF family (BAFF)-R is the principal BAFF receptor facilitating BAFF costimulation of circulating T and B cells. J Immunol 2004 173 : 807 817.
52. Lai Kwan Lam Q, King Hung Ko O, Zheng BJ, Lu L. Local BAFF gene silencing suppresses Th17-cell generation and ameliorates autoimmune arthritis. Proc Natl Acad Sci USA 2008 105 : 14993 14998.
53. Chang SK, Mihalcik SA, Jelinek DF. B lymphocyte stimulator regulates adaptive immune responses by directly promoting dendritic cell maturation. J Immunol 2008 180 : 7394 7403.
54. Wilson LE, Widman D, Dikman SH, Gorevic PD. Autoimmune disease complicating antiviral therapy for hepatitis C virus infection. Semin Arthritis Rheum 2002 32 : 163 173.
55. Mathian A, Weinberg A, Gallegos M, Banchereau J, Koutouzov S. IFN-alpha induces early lethal lupus in preautoimmune (New Zealand Black × New Zealand White) F1 but not in BALB/c mice. J Immunol 2005 174 : 2499 2506.
56. Mohan AK, Edwards ET, Cote TR, Siegel JN, Braun MM. Drug-induced systemic lupus erythematosus and TNF-alpha blockers. Lancet 2002 360 : 646.
57. Krumbholz M, Faber H, Steinmeyer F et al. Interferon-beta increases BAFF levels in multiple sclerosis: implications for B cell autoimmunity. Brain 2008 131 : 1455 1463.
58. Bitsch A, Dressel A, Meier K et al. Autoantibody synthesis in primary progressive multiple sclerosis patients treated with interferon beta-1b. J Neurol 2004 251 : 1498 1501. (Pubitemid 40169474)
59. Bonaci-Nikolic B, Jeremic I, Andrejevic S, Sefik-Bukilica M, Stojsavljevic N, Drulovic J. Anti-double stranded DNA and lupus syndrome induced by interferon-beta therapy in a patient with multiple sclerosis. Lupus 2009 18 : 78 80.
60. Lavie F, Miceli-Richard C, Ittah M, Sellam J, Gottenberg JE, Mariette X. Increase of B cell-activating factor of the TNF family (BAFF) after rituximab treatment: insights into a new regulating system of BAFF production. Ann Rheum Dis 2007 66 : 700 703.
61. Ramanujam M, Davidson A. BAFF blockade for systemic lupus erythematosus - will the promise be fulfilled? Immunol Rev 2008 223 : 156 174.
62. Furie R, Stohl W, Ginzler EM et al. Biologic activity and safety of belimumab, a neutralizing anti-B-lymphocyte stimulator (BLyS) monoclonal antibody: a phase I trial in patients with systemic lupus erythematosus. Arthritis Res Ther 2008 10 : R109.
63. Wallace DJ, Stohl W, Furie RA et al. A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus. Arthritis Care Res 2009 (in press).
64. Tak PP, Thurlings RM, Rossier C et al. Atacicept in patients with rheumatoid arthritis: results of a multicenter, phase Ib, double-blind, placebo-controlled, dose-escalating, single- and repeated-dose study. Arthritis Rheum 2008 58 : 61 72.
65. Bosello S, Youinou P, Daridon C et al. Concentrations of BAFF correlate with autoantibody levels, clinical disease activity, and response to treatment in early rheumatoid arthritis. J Rheumatol 2008 35 : 1256 1264.
66. Zhang M, Ko KH, Lam QL et al. Expression and function of TNF family member B cell-activating factor in the development of autoimmune arthritis. Int Immunol 2005 17 : 1081 1092.
67. Ohata J, Zvaifler NJ, Nishio M et al. Fibroblast-like synoviocytes of mesenchymal origin express functional B cell-activating factor of the TNF family in response to proinflammatory cytokines. J Immunol 2005 174 : 864 870.
68. Alsaleh G, Messer L, Semaan N et al. BAFF synthesis by rheumatoid synoviocytes is positively controlled by alpha5beta1 integrin stimulation and is negatively regulated by tumor necrosis factor alpha and Toll-like receptor ligands. Arthritis Rheum 2007 56 : 3202 3214.
69. Dalakas MC. B cells as therapeutic targets in autoimmune neurological disorders. Nat Clin Pract Neurol 2008 4 : 557 567.
70. Chaudhuri A, Behan PO. Rituximab in relapsing-remitting multiple sclerosis. N Engl J Med 2008 358 : 2646 author reply 7.
71. Huntington ND, Tomioka R, Clavarino C et al. A BAFF antagonist suppresses experimental autoimmune encephalomyelitis by targeting cell-mediated and humoral immune responses. Int Immunol 2006 18 : 1473 1485.
72. Daridon C, Devauchelle V, Hutin P et al. Aberrant expression of BAFF by B lymphocytes infiltrating the salivary glands of patients with primary Sjogren's syndrome. Arthritis Rheum 2007 56 : 1134 1144. (Pubitemid 46608638)
73. Ittah M, Miceli-Richard C, Eric Gottenberg J et al. B cell-activating factor of the tumor necrosis factor family (BAFF) is expressed under stimulation by interferon in salivary gland epithelial cells in primary Sjogren's syndrome. Arthritis Res Ther 2006 8 : R51.
74. Lavie F, Miceli-Richard C, Quillard J, Roux S, Leclerc P, Mariette X. Expression of BAFF (BLyS) in T cells infiltrating labial salivary glands from patients with Sjogren's syndrome. J Pathol 2004 202 : 496 502.
75. Gottenberg JE, Cagnard N, Lucchesi C et al. Activation of IFN pathways and plasmacytoid dendritic cell recruitment in target organs of primary Sjogren's syndrome. Proc Natl Acad Sci USA 2006 103 : 2770 2775.
76. Szodoray P, Jellestad S, Teague MO, Jonsson R. Attenuated apoptosis of B cell activating factor-expressing cells in primary Sjogren's syndrome. Lab Invest 2003 83 : 357 365.
77. Mariette X, Roux S, Zhang J et al. The level of BLyS (BAFF) correlates with the titre of autoantibodies in human Sjogren's syndrome. Ann Rheum Dis 2003 62 : 168 171.
78. Khare SD, Sarosi I, Xia XZ et al. Severe B cell hyperplasia and autoimmune disease in TALL-1 transgenic mice. Proc Natl Acad Sci USA 2000 97 : 3370 3375.
79. Zhang J, Roschke V, Baker KP et al. Cutting edge: a role for B lymphocyte stimulator in systemic lupus erythematosus. J Immunol 2001 166 : 6 10.
80. Cheema GS, Roschke V, Hilbert DM, Stohl W. Elevated serum B lymphocyte stimulator levels in patients with systemic immune-based rheumatic diseases. Arthritis Rheum 2001 44 : 1313 1319.
81. Stohl W, Metyas S, Tan SM et al. B lymphocyte stimulator overexpression in patients with systemic lupus erythematosus: longitudinal observations. Arthritis Rheum 2003 48 : 3475 3486.
82. Ettinger R, Sims GP, Robbins R et al. IL-21 and BAFF/BLyS synergize in stimulating plasma cell differentiation from a unique population of human splenic memory B cells. J Immunol 2007 178 : 2872 2882.
83. Doreau A, Belot A, Bastid J et al. Interleukin 17 acts in synergy with B cell-activating factor to influence B cell biology and the pathophysiology of systemic lupus erythematosus. Nat Immunol 2009 10 : 778 785.
84. Ramanujam M, Wang X, Huang W et al. Similarities and differences between selective and nonselective BAFF blockade in murine SLE. J Clin Invest 2006 116 : 724 734.
85. Ramanujam M, Wang X, Huang W et al. Mechanism of action of transmembrane activator and calcium modulator ligand interactor-Ig in murine systemic lupus erythematosus. J Immunol 2004 173 : 3524 3534.
86. Kahn P, Ramanujam M, Huang W et al. Prevention of murine anti-phospholipid syndrome by BAFF blockade. Arthritis Rheum 2008 58 : 2824 2834.
87. Connor BP O', Raman VS, Erickson LD et al. BCMA is essential for the survival of long-lived bone marrow plasma cells. J Exp Med 2004 199 : 91 8.
88. Benson MJ, Dillon SR, Castigli E et al. Cutting edge: the dependence of plasma cells and independence of memory B cells on BAFF and APRIL. J Immunol 2008 180 : 3655 3659.
89. Liu W, Szalai A, Zhao L et al. Control of spontaneous B lymphocyte autoimmunity with adenovirus-encoded soluble TACI. Arthritis Rheum 2004 50 : 1884 1896.
90. Singh RR, Saxena V, Zang S et al. Differential contribution of IL-4 and STAT6 vs STAT4 to the development of lupus nephritis. J Immunol 2003 170 : 4818 4825.
91. Erickson LD, Lin LL, Duan B, Morel L, Noelle RJ. A genetic lesion that arrests plasma cell homing to the bone marrow. Proc Natl Acad Sci USA 2003 100 : 12905 12910.
92. Carter RH. A role for BLyS in tissue inflammation? Arthritis Rheum 2003 48 : 882 885.
93. Cohen SB. Updates from B Cell trials: efficacy. J Rheumatol 2006 77 : 12 17.
94. Dall'Era M, Chakravarty E, Wallace D et al. Reduced B lymphocyte and immunoglobulin levels after atacicept treatment in patients with systemic lupus erythematosus: results of a multicenter, phase Ib, double-blind, placebo-controlled, dose-escalating trial. Arthritis Rheum 2007 56 : 4142 4150.